Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer.
We performed bulk-RNA sequencing analysis from KRAS G12V mouse tumor nodules from different treatment. Overall design: KRAS G12V mutant mice with lung tumors were treated with either vehicle or dTAGV-1. Tumor nodules were collected for sequencing.